Panacea Index Logo

Command Palette

Search for a command to run...

Melatonin Administration from 2000 to 2020 to Human Newborns with Hypoxic-Ischemic Encephalopathy.

American journal of perinatology
June 1, 2022
Gabriella D'angelo et al. (4 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to summarize the advantages and limitations of melatonin investigations for treating hypoxic-ischemic encephalopathy (HIE) in term-born infants.

Results Summary

Melatonin shows promise for treating perinatal asphyxia due to its antioxidant and anti-inflammatory effects, but clinical trials with sufficient sample sizes in newborns are lacking. Synergistic use with hypothermia may improve neurological outcomes in HIE.

Population

Term-born infants with hypoxic-ischemic encephalopathy (HIE).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (3)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin
neutral
perinatal asphyxia
-
-
is a promising molecule for the treatment of
#1
hypothermia associated with melatonin treatment
increase
neurological outcome
infants with HIE
-
may improve
#2
melatonin
decrease
oxidative stress
animals
-
efficacy in reducing
#3
Abstract

Hypoxic-ischemic encephalopathy (HIE) is the main cause of long-term neurodevelopmental morbidity in term born infants worldwide. Melatonin is a hormone with antioxidant and anti-inflammatory effects that make it a promising molecule for the treatment of perinatal asphyxia. Probably, the synergistic use of hypothermia associated with melatonin treatment may improve the neurological outcome in infants with HIE. In the past 20 years, the efficacy of melatonin in reducing oxidative stress has been demonstrated in animals; however, clinical trials with sufficient sample size of newborns are lacking to date. Since in 2000 we were among the first to study the neuroprotective properties of melatonin on infants, in this review, we want to summarize the advantages and limitations of the investigations conducted to date. KEY POINTS: · HIE is the main cause of morbidity in term born infants worldwide.. · Melatonin is a promising molecule for the treatment of perinatal asphyxia.. · This review summarizes advantages and limitations of the investigations conducted on melatonin..

Medical Subject Headings (MeSH)
AsphyxiaAsphyxia NeonatorumFemaleHumansHypothermia, InducedHypoxia-Ischemia, BrainInfant, NewbornMelatoninPregnancy
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality60/10
Citation Metrics
Total Citations11
Citations/Year3.7
Relative Citation Ratio2.05
NIH Percentile75.2%
Research Impact Scores
APT Score0.75
Weight Score2.25
Normalized Score0.60
Related Supplements